The demo accomplished both of those its Major endpoints, with semaglutide two.4 mg demonstrating statistically significant and remarkable improvements in liver fibrosis without any worsening of steatohepatitis, and also resolution of steatohepatitis without having worsening of liver fibrosis in people with MASH as compared to placebo.1I possess the